Literature DB >> 33657097

Therapeutic advances in the topical treatment of cutaneous leishmaniasis: A review.

Marium Azim1, Saeed Ahmad Khan1, Saleem Ullah1, Shafiq Ullah1, Syed Ishtiaq Anjum2.   

Abstract

Cutaneous leishmaniasis has been endemic since decades. Millions of cases are reported worldwide specially in developing and underdeveloped countries. There are 2 major types of cutaneous leishmaniasis based on the causating species found in different regions of the world. These include New and Old World cutaneous leishmaniasis, which are self-healing, but if not treated, these may cause severe scars and many other complications like mucosal involvement. The conventional gold standard treatment for both types is mainly intralesional or parenteral administration of antimonial. Lately, a great deal of research has been done on development of topical treatment based on single agent or combination therapy. This review summarizes the current state of literature regarding therapeutic outcome of topical treatment against cutaneous leishmaniasis caused by different species in different regions.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33657097      PMCID: PMC7928440          DOI: 10.1371/journal.pntd.0009099

Source DB:  PubMed          Journal:  PLoS Negl Trop Dis        ISSN: 1935-2727


  67 in total

1.  Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala.

Authors:  B A Arana; C E Mendoza; N R Rizzo; A Kroeger
Journal:  Am J Trop Med Hyg       Date:  2001-11       Impact factor: 2.345

2.  Transient effect of topical treatment of cutaneous leishmaniasis with imiquimod.

Authors:  Josef Seeberger; Saleh Daoud; Johannes Pammer
Journal:  Int J Dermatol       Date:  2003-07       Impact factor: 2.736

3.  Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major.

Authors:  Babak Shazad; Babak Abbaszadeh; Ali Khamesipour
Journal:  Eur J Dermatol       Date:  2005 Mar-Apr       Impact factor: 3.328

Review 4.  Advances in leishmaniasis.

Authors:  Henry W Murray; Jonathan D Berman; Clive R Davies; Nancy G Saravia
Journal:  Lancet       Date:  2005 Oct 29-Nov 4       Impact factor: 79.321

5.  In vivo studies on the antileishmanial activity of buparvaquone and its prodrugs.

Authors:  Tracy Garnier; Antti Mäntylä; Tomi Järvinen; Jayne Lawrence; Marc Brown; Simon Croft
Journal:  J Antimicrob Chemother       Date:  2007-08-21       Impact factor: 5.790

Review 6.  Imiquimod and resiquimod as novel immunomodulators.

Authors:  D H Dockrell; G R Kinghorn
Journal:  J Antimicrob Chemother       Date:  2001-12       Impact factor: 5.790

Review 7.  Miltefosine: oral treatment of leishmaniasis.

Authors:  Jaime Soto; Paula Soto
Journal:  Expert Rev Anti Infect Ther       Date:  2006-04       Impact factor: 5.091

8.  Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot study.

Authors:  Jaime M Soto; Julia T Toledo; Patricia Gutierrez; Margarita Arboleda; Ruben S Nicholls; Julio R Padilla; Jonathan D Berman; Charles K English; Max Grogl
Journal:  Am J Trop Med Hyg       Date:  2002-02       Impact factor: 2.345

9.  The activity of hydroxynaphthoquinones against Leishmania donovani.

Authors:  S L Croft; J Hogg; W E Gutteridge; A T Hudson; A W Randall
Journal:  J Antimicrob Chemother       Date:  1992-12       Impact factor: 5.790

10.  Topical paromomycin for New World cutaneous leishmaniasis.

Authors:  Néstor Sosa; Juan Miguel Pascale; Ana I Jiménez; Jeanne A Norwood; Mara Kreishman-Detrick; Peter J Weina; Kendra Lawrence; William F McCarthy; Ryan C Adams; Charles Scott; Janet Ransom; Douglas Tang; Max Grogl
Journal:  PLoS Negl Trop Dis       Date:  2019-05-02
View more
  5 in total

Review 1.  Epigenetic paradigms/exemplars of the macrophage: inflammasome axis in Leishmaniasis.

Authors:  Manei M Aljedaie
Journal:  Mol Cell Biochem       Date:  2022-05-20       Impact factor: 3.396

2.  In silico screening, molecular dynamic simulations, and in vitro activity of selected natural compounds as an inhibitor of Leishmania donovani 3-mercaptopyruvate sulfurtransferase.

Authors:  Vishnu Kant; Pawan Kumar; Ravi Ranjan; Prakash Kumar; Debabrata Mandal; Saravanan Vijayakumar
Journal:  Parasitol Res       Date:  2022-05-10       Impact factor: 2.383

3.  Effect of topical berberine in murine cutaneous leishmaniasis lesions.

Authors:  Alba Calvo; Esther Moreno; Irati Aldalur; Carmen Sanmartín; Esther Larrea; Elena González-Peñas; Juan Manuel Irache; Socorro Espuelas
Journal:  J Antimicrob Chemother       Date:  2022-03-31       Impact factor: 5.790

4.  Synthesis, Structure and Antileishmanial Evaluation of Endoperoxide-Pyrazole Hybrids.

Authors:  Patrícia S M Amado; Inês C C Costa; José A Paixão; Ricardo F Mendes; Sofia Cortes; Maria L S Cristiano
Journal:  Molecules       Date:  2022-08-24       Impact factor: 4.927

5.  In Vitro Metabolism of Helenalin Acetate and 11α,13-Dihydrohelenalin Acetate: Natural Sesquiterpene Lactones from Arnica.

Authors:  Franziska M Jürgens; Matthias Behrens; Hans-Ulrich Humpf; Sara M Robledo; Thomas J Schmidt
Journal:  Metabolites       Date:  2022-01-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.